Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System (CTCs)

June 23, 2026 updated by: Tomsk National Research Medical Center of the Russian Academy of Sciences

Phenotypic Spectrum of Circulating Tumor Cell Populations as Markers of Liquid Biopsy in Tumors of the Female Reproductive System

The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patients with tumors of the female reproductive system (breast cancer, endometrial cancer, and ovarian cancer).

The primary objective are:

  1. To assess the presence and number of different populations of CTCs at different time points (before biopsy, before surgery, and after surgery).
  2. To assess the relationships of different CTCs populations prior to treatment initiation with the effects of neoadjuvant chemotherapy and the risks of recurrence and metastases.
  3. To assess the molecular profiles of different CTCs populations in the blood and in ascitic fluid.

The secondary objective is to compare the multicolor flow cytometry results with data of ultrasound, CT and/or MRI, serum tumor markers, and immunohistochemical studies in patients with breast cancer, endometrial cancer and ovarian cancer

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The overall goal is to study the diagnostic and prognostic efficacy of various CTC populations as liquid biopsy markers in tumors of the female reproductive system (breast cancer, endometrial cancer, and ovarian cancer).

Phase I study:

Determination of different populations of CTCs in blood and ascitic fluid (if any) prior to treatment.

The main objectives of the study:

  1. To assess the presence and number of different CTC populations at different time points (before biopsy and before surgery) using multicolor flow cytometry.
  2. To assess the relationships between different CTCs populations prior to treatment initiation with the effects of neoadjuvant chemotherapy and the risks of recurrence and metastases.
  3. To assess the molecular profiles of different CTCs populations in the blood and in ascitic fluid.

Additional research tasks:

To compare the multicolor flow cytometry results with the data of ultrasound, CT and/or MRI, serum tumor markers, and immunohistochemical studies in patients with breast cancer, endometrial cancer, and ovarian cancer Methodology: Open-label, exploratory, single centre study. Blood and ascitic fluid collected from subjects (if available)

Study Type

Observational

Enrollment (Actual)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russia
    • Tomsk Oblast
      • Tomsk, Tomsk Oblast, Russia, 634050
        • Evgeniya Kaigorodova

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Women over 18 years of age.

Description

Inclusion Criteria:

  • Subject is > 18 years of age A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential.
  • Clinical and radiological diagnosis of breast cancer or Ovarian cancer or Endometrial Cancer General satisfactory condition (according to the ECOG scale ≤2) Subject is capable to undergo the diagnostic investigations to be performed in the study
  • Informed consent

Exclusion Criteria:

  • Active current autoimmune disease or history of autoimmune disease

    • Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)
    • Known HIV positive or chronically active hepatitis B or C The subject has multiple primary malignant tumors

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Breast cancer
At least eighty five subjects with breast cancer
Other: Taking 5 ml of venous blood at different time intervals
Other Names:
  • Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy
Other: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Ovarian cancer
At least 32 subjects with ovarian cancer
Other: Taking 5 ml of venous blood at different time intervals
Other Names:
  • Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy
Other: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Endometrial Cancer
At least 33 subjects with endometrial cancer
Other: Taking 5 ml of venous blood at different time intervals
Other Names:
  • Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy
Other: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Healthy control
30 healthy volunteers
Other: Taking 5 ml of venous blood at different time intervals
Other Names:
  • Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy
Suspected malignant tumor non-verified
Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined
Other: Taking 5 ml of venous blood at different time intervals
Other Names:
  • Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy
Other: Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CTC phenotype
Time Frame: 6 hours

Different populations of CTCs are evaluated by multicolor flow cytometry and may include:

СTC, ascitic tumor cells with stemness features without EMT features; CTC, ascitic tumor cells without stemness and EMT features; CTC, ascitic tumor cells without stemness features and with EMT features; CTC, ascitic tumor cells with stemness features and EMT features; Atypical/hybrid cells without stemness features; Atypical cells.
6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Investigators

  • Principal Investigator: Evgeniya Kaigorodova, Tomsk NRMC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 14, 2014

Primary Completion (Actual)

December 1, 2022

Study Completion (Actual)

December 1, 2022

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

March 23, 2021

First Posted (Actual)

March 26, 2021

Study Record Updates

Last Update Posted (Actual)

June 24, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ORI-3E

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Taking 5 ml of venous blood at different time intervals

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe